ReviewFrontiers in neuroscience2020
Somatostatin, Olfaction, and Neurodegeneration.
Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Gut microbiota as a modulator of HDAC: insights into Alzheimer's disease treatment.Pharmacological reports : PR · 2026Review
- Modeling late-onset Alzheimer's disease neuropathology via direct neuronal reprogramming.Science (New York, N.Y.) · 2024Article
- Article
- The effect of the apolipoprotein E ε4 allele and olfactory function on odor identification networks.Brain and behavior · 2024Article
- Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.Annals of clinical and translational neurology · 2024Article
- Olfactory deficits in aging and Alzheimer's-spotlight on inhibitory interneurons.Frontiers in neuroscience · 2024Review
- Transition metal ions and neurotransmitters: coordination chemistry and implications for neurodegeneration.RSC chemical biology · 2023Review
- Cocaine- and Amphetamine-Regulated Transcript (CART) Peptide Is Co-Expressed with Parvalbumin, Neuropeptide Y and Somatostatin in the Claustrum of the Chinchilla.Animals : an open access journal from MDPI · 2023Article
- Common molecular signatures between coronavirus infection and Alzheimer's disease reveal targets for drug development.bioRxiv : the preprint server for biology · 2023Article
- Common Molecular Signatures Between Coronavirus Infection and Alzheimer's Disease Reveal Targets for Drug Development.Journal of Alzheimer's disease : JAD · 2023Article
- Olfactory function changes and the predictive performance of the Chinese Smell Identification Test in patients with mild cognitive impairment and Alzheimer's disease.Frontiers in aging neuroscience · 2023Article
- Review
- Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats.Journal of molecular neuroscience : MN · 2021Article
- Somatostatin and Astroglial Involvement in the Human Limbic System in Alzheimer's Disease.International journal of molecular sciences · 2021Article
- Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System.Frontiers in endocrinology · 2021Review
- Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.Frontiers in immunology · 2021Article
- Regulatory Mechanisms of Somatostatin Expression.International journal of molecular sciences · 2020Review
- The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases.Translational neurodegeneration · 2020Review
- GABAergic Inhibitory Interneuron Deficits in Alzheimer's Disease: Implications for Treatment.Frontiers in neuroscience · 2020Review
- Identification of potential short-chain fatty acid biomarkers in Alzheimer's disease through bioinformatics analysis.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's and Parkinson's diseases are the most prevalent neurodegenerative disorders in aging. Hyposmia has been described as an early symptom that can precede cognitive and motor deficits by decades. Certain regions within the olfactory system, such as the anterior olfactory nucleus, display the neuropathological markers tau and amyloid-β or α-synuclein from the earliest stages of disease progression in a preferential manner. Specific neuronal subpopulations, namely those expressing somatostatin (SST), are preferentially affected throughout the olfactory and limbic systems. SST is a neuropeptide present in a subpopulation of GABAergic interneurons throughout the brain and its main function is to inhibit principal neurons and/or other interneurons. It has been reported that SST expression is reduced by 50% in Alzheimer's disease and that it is related to the formation of Aβ oligomers. The mechanisms underlying the preferential vulnerability of SST-expressing neurons in Alzheimer's disease (and, to a minor extent, in Parkinson's disease) are not known but analysis of the available data could shed light on their etiology. This short review aims to update the knowledge of functional features of somatostatin within the olfactory system and its role in olfactory deficits during neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.